BR112022012594A2 - Dosagem de gama-hidroxibutirato (ghb) - Google Patents
Dosagem de gama-hidroxibutirato (ghb)Info
- Publication number
- BR112022012594A2 BR112022012594A2 BR112022012594A BR112022012594A BR112022012594A2 BR 112022012594 A2 BR112022012594 A2 BR 112022012594A2 BR 112022012594 A BR112022012594 A BR 112022012594A BR 112022012594 A BR112022012594 A BR 112022012594A BR 112022012594 A2 BR112022012594 A2 BR 112022012594A2
- Authority
- BR
- Brazil
- Prior art keywords
- ghb
- hydroxybutyrate
- gamma
- dosage
- narcolepsy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953288P | 2019-12-24 | 2019-12-24 | |
| US202062993372P | 2020-03-23 | 2020-03-23 | |
| US202063000547P | 2020-03-27 | 2020-03-27 | |
| US202063052676P | 2020-07-16 | 2020-07-16 | |
| PCT/US2020/066561 WO2021133778A1 (en) | 2019-12-24 | 2020-12-22 | Gamma-hydroxybutyrate (ghb) dosing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012594A2 true BR112022012594A2 (pt) | 2022-09-06 |
Family
ID=74191949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012594A BR112022012594A2 (pt) | 2019-12-24 | 2020-12-22 | Dosagem de gama-hidroxibutirato (ghb) |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20210186907A1 (https=) |
| EP (1) | EP4081204A1 (https=) |
| JP (1) | JP2023508975A (https=) |
| KR (1) | KR20220119429A (https=) |
| CN (1) | CN115209885A (https=) |
| AU (1) | AU2020414694A1 (https=) |
| BR (1) | BR112022012594A2 (https=) |
| CA (1) | CA3162974A1 (https=) |
| CL (1) | CL2022001743A1 (https=) |
| CO (1) | CO2022010330A2 (https=) |
| IL (1) | IL294176A (https=) |
| MX (1) | MX2022007968A (https=) |
| TW (1) | TW202135790A (https=) |
| WO (1) | WO2021133778A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| BR112021006027A2 (pt) | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US12582622B2 (en) | 2020-10-08 | 2026-03-24 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1140061T3 (da) | 1998-12-23 | 2003-08-25 | Orphan Medical Inc | Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi |
| ES2383673T3 (es) | 2000-09-22 | 2012-06-25 | Jpi Commercial, Llc | Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos |
| US7610153B2 (en) * | 2002-02-13 | 2009-10-27 | Virginia Commonwealth University | Multi-drug titration and evaluation |
| US7668730B2 (en) | 2002-12-17 | 2010-02-23 | JPI Commercial, LLC. | Sensitive drug distribution system and method |
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8771735B2 (en) | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| CN102946869B (zh) * | 2010-05-04 | 2016-08-03 | 爵士制药有限公司 | γ-羟基丁酸的速释制剂及剂型 |
| US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US9801852B2 (en) | 2013-08-30 | 2017-10-31 | Jazz Pharmaceuticals, Inc. | Devices and methods for facilitating and controlling use of a medication |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
-
2020
- 2020-12-22 US US17/130,769 patent/US20210186907A1/en not_active Abandoned
- 2020-12-22 TW TW109145587A patent/TW202135790A/zh unknown
- 2020-12-22 IL IL294176A patent/IL294176A/en unknown
- 2020-12-22 WO PCT/US2020/066561 patent/WO2021133778A1/en not_active Ceased
- 2020-12-22 CN CN202080097472.7A patent/CN115209885A/zh active Pending
- 2020-12-22 KR KR1020227024876A patent/KR20220119429A/ko not_active Withdrawn
- 2020-12-22 BR BR112022012594A patent/BR112022012594A2/pt unknown
- 2020-12-22 MX MX2022007968A patent/MX2022007968A/es unknown
- 2020-12-22 AU AU2020414694A patent/AU2020414694A1/en not_active Abandoned
- 2020-12-22 CA CA3162974A patent/CA3162974A1/en active Pending
- 2020-12-22 EP EP20842864.9A patent/EP4081204A1/en not_active Withdrawn
- 2020-12-22 JP JP2022539046A patent/JP2023508975A/ja active Pending
-
2021
- 2021-08-06 US US17/396,104 patent/US20210361601A1/en active Pending
-
2022
- 2022-06-24 CL CL2022001743A patent/CL2022001743A1/es unknown
- 2022-07-22 CO CONC2022/0010330A patent/CO2022010330A2/es unknown
-
2024
- 2024-05-01 US US18/652,039 patent/US20240285560A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021133778A1 (en) | 2021-07-01 |
| IL294176A (en) | 2022-08-01 |
| US20210186907A1 (en) | 2021-06-24 |
| JP2023508975A (ja) | 2023-03-06 |
| EP4081204A1 (en) | 2022-11-02 |
| CO2022010330A2 (es) | 2022-10-21 |
| CN115209885A (zh) | 2022-10-18 |
| US20240285560A1 (en) | 2024-08-29 |
| KR20220119429A (ko) | 2022-08-29 |
| AU2020414694A1 (en) | 2022-08-18 |
| US20210361601A1 (en) | 2021-11-25 |
| TW202135790A (zh) | 2021-10-01 |
| CL2022001743A1 (es) | 2023-02-10 |
| CA3162974A1 (en) | 2021-07-01 |
| MX2022007968A (es) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| CL2022001189A1 (es) | Anticuerpos para cd40. (divisional de solicitud n° 2017003427) | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| CL2018002703A1 (es) | Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291) | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| BR112013022789A2 (pt) | composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2 | |
| BR112022008294A2 (pt) | Composições de profármaco e métodos de tratamento | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
| BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| BR112021021060A2 (pt) | Anticorpos anti-cd38 e formulações | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
| EA202090666A1 (ru) | Применение содержащей бензоат композиции для лечения глициновой энцефалопатии | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |